Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Aegerion sales and marketing update

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Cambridge, Mass. Business: Endocrine/Metabolic The German Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that Lojuxta …

    Published on 10/5/2015
  • BioSpecifics, Endo, Swedish Orphan Biovitrum sales and marketing update

    BioSpecifics Technologies Corp. (NASDAQ:BSTC), Lynbrook, N.Y. Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Business: Musculoskeletal NICE …

    Published on 10/5/2015
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business:Cancer The U.K.s NICE issued final draft guidance recommending against Abraxane nab-paclitaxel to treat pancreatic cancer in combination with gemcitabine. The agency …

    Published on 10/5/2015
  • Chugai, Roche sales and marketing update

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Autoimmune The U.K.s NICE issued a final appraisal determination (FAD) recommending RoActemra …

    Published on 10/5/2015
  • Clinigen Group, Neuraltus sales and marketing update

    Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Neuraltus Pharmaceuticals Inc., Palo Alto, Calif. Business: Neurology The companies launched a managed access program in Europe for Neuraltus NP001 to treat …

    Published on 10/5/2015
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The U.K.s NICE issued preliminary draft recommending against Cyramza ramucirumab from Eli Lilly to treat advanced gastric cancer or gastro-esophageal …

    Published on 10/5/2015
  • Eli Lilly, Sumitomo Dainippon sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Business: Endocrine/Metabolic Eli Lilly and Sumitomo Dainippon launched Trulicity dulaglutide in Japan to …

    Published on 10/5/2015
  • Foundation Medicine sales and marketing update

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. Business: Genomics Foundation launched GeneKit for interpreting and reporting genomic information to inform therapeutic decisions for cancer. The cloud-based …

    Published on 10/5/2015
  • MDxHealth sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Business: Diagnostic Tufts Health Plan will cover MDxHealths ConfirmMDx for Prostate Cancer test. MDxHealth markets the epigenetic laboratory-developed test (LDT) to assess…

    Published on 10/5/2015
  • Acura, Egalet sales and marketing update

    Acura Pharmaceuticals Inc. (NASDAQ:ACUR), Palatine, Ill. Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Business: Neurology Egalet launched Oxaydo oxycodone in the U.S. for managing acute and chronic moderate to severe pain. …

    Published on 9/28/2015
  • Boehringer Ingelheim sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Pulmonary The U.K.s NICE issued preliminary draft guidance recommending Ofev nintedanib from Boehringer to treat idiopathic pulmonary fibrosis (IPF) -- its …

    Published on 9/28/2015
  • Helsinn, Chugai sales and marketing update

    Helsinn Healthcare S.A., Lugano, Switzerland Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Business: Gastrointestinal Chugai launched Akynzeo netupitant/palonosetron in the U.K. to prevent chemotherapy-…

    Published on 9/28/2015
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer The U.K.s NICE issued a final appraisal determination (FAD) recommending Keytruda pembrolizumab to treat unresectable or metastatic melanoma in patients …

    Published on 9/28/2015
  • NanoString sales and marketing update

    NanoString Technologies Inc. (NASDAQ:NSTG), Seattle, Wash. Business: Functional genomics NanoString launched nCounter RNA:Protein PanCancer Immune Profiling Panel for gene and protein expression analysis in cancer. The …

    Published on 9/28/2015
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic The German Institute for Quality and Efficiency in Health Care (IQWiG) said data from Novo Nordisk supporting Xultophy insulin …

    Published on 9/28/2015
  • Pathway Genomics sales and marketing update

    Pathway Genomics Corp., San Diego, Calif. Business: Diagnostic Pathway launched CancerIntercept Detect to diagnose cancer and CancerIntercept Monitor to monitor patients with cancer. The liquid biopsy test uses DNA …

    Published on 9/28/2015
  • PeriRx sales and marketing update

    PeriRx LLC, Broomall, Pa. Business: Diagnostic PeriRx launched SaliMark OSCC test to diagnose oral squamous cell carcinoma. The multimarker panel detects mRNA markers in saliva samples.

    Published on 9/28/2015
  • Rockwell Medical sales and marketing update

    Rockwell Medical Inc. (NASDAQ:RMTI), Wixom, Mich. Business: Hematology Rockwell launched Triferic ferric pyrophosphate citrate in the U.S. for the replacement of iron to maintain hemoglobin in adult patients with …

    Published on 9/28/2015
  • Turing Pharmaceuticals sales and marketing update

    Turing Pharmaceuticals AG, New York, N.Y. Business: Infectious Turings CEO Martin Shkreli told news outlets that the price of antiparasitic drug Daraprim pyrimethamine will be lowered to allow the company to make a …

    Published on 9/28/2015
  • AbbVie, Bristol-Myers, Merck, Pfizer, Roche, UCB sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, …

    Published on 9/21/2015
  • Acino sales and marketing update

    Acino Holding AG, Aesch, Switzerland Business: Neurology, Generics Acino launched a generic version of Exelon Patch rivastigmine from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) in the U.S. Exelon Patch, an …

    Published on 9/21/2015
  • Gilead, Fair Pricing Coalition sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Fair Pricing Coalition, San Francisco, Calif. Business: Infectious The Fair Pricing Coalition (FPC) petitioned Gilead to apply cost-containment strategies in the…

    Published on 9/21/2015
  • Insight Genetics sales and marketing update

    Insight Genetics Inc., Nashville, Tenn. Business: Diagnostic Insight launched Insight RET Screen to identify patients with non-small cell lung cancer (NSCLC) who will benefit from ret proto-oncogene (RET) inhibitor …

    Published on 9/21/2015
  • Par Pharmaceutical sales and marketing update

    Par Pharmaceutical Holdings Inc., Chestnut Ridge, N.Y. Business: Endocrine/Metabolic, Generics Par launched its testosterone gel 1%, a generic version of AndroGel 1% from AbbVie Inc. (NYSE:ABBV, Chicago, Ill.). AndroGel…

    Published on 9/21/2015
  • WuXi PharmaTech, Fudan University sales and marketing update

    WuXi PharmaTech Inc. (NYSE:WX), Shanghai, China Fudan University, Shanghai, China Business: Genomics The WuXi NextCODE subsidiary of WuXi PharmaTech said it would provide genetic testing services for the Childrens …

    Published on 9/21/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993